Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

NCT02614066 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT02614066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02614066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1/2
Overall status
Completed
Start date
March 7, 2016
Completion date
November 3, 2023
Enrollment
125 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-precursor acute lymphoblastic leukemia